Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

45.18 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Why Shares of Kymera Therapeutics Jumped on Tuesday
The company had a big bounce after hitting a 52-week low the day before. 
Via The Motley Fool
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma
From Kymera Therapeutics, Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Kymera Therapeutics
Via Benzinga
Verizon To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Tuesday
Stifel raised the price target for Hersha Hospitality Trust (NYSE: HT) from $8.75 to $10. Stifel analyst Simon Yarmak downgraded the stock from Buy to Hold. Hersha Hospitality Trust shares fell 0.5% to... 
Via Benzinga
Expert Ratings for Kymera Therapeutics
Via Benzinga
What 5 Analyst Ratings Have To Say About Kymera Therapeutics
Via Benzinga
Kymera Therapeutics's Return On Capital Employed Insights
Via Benzinga
Analyst Ratings for Kymera Therapeutics
Via Benzinga
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2023
Via Benzinga
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress
A single dose of KT-253 drives tumor regression and demonstrates differentiated pharmacology compared to small molecule inhibitor (SMI) in preclinical models of ALL and AML 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Why Guidewire Software Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers MultiMetaVerse Holdings Limited (NASDAQ: MMV) gained 236% to $3.1592 after the company announced it signed a non-binding term sheet to acquire an equity stake in Taomee group. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Kymera Therapeutics to Participate in Upcoming June Investor Conference
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium
From Kymera Therapeutics, Inc.
Via GlobeNewswire
7 Growth Stocks That Could Double Your Money in 2023
For investors that really want to roll the dice, these are the enticing growth stocks that could double your money. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2023
Via Benzinga
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4
Company also presenting at upcoming investor conferences 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
7 Biotech Stocks to Buy for 100% Returns
If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio. 
Via InvestorPlace
Join These Motley Fool Investors for "The Market Cap Game Show"
Multiplying the number of shares by the share price is just step one. 
Via The Motley Fool
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.